Generian and Mitobridge, an Astellas company, have entered into a collaboration and license agreement to discover and develop small molecules for undruggable therapeutic targets. The deal, which involves an undisclosed upfront payment and up to US$180 M in milestone payments, will leverage Generian’s proprietary drug discovery platformfor diseases that have limited treatment options. The deal follows a flurry of deals from Astellas as the big pharma attempts to strengthen its portfolio following recent pipeline setbacks.